Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.

Liu X, Mayes MD, Tan FK, Wu M, Reveille JD, Harper BE, Draeger HT, Gonzalez EB, Assassi S.

Arthritis Rheum. 2013 Jan;65(1):226-35. doi: 10.1002/art.37742.

2.

Systemic sclerosis and lupus: points in an interferon-mediated continuum.

Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, Chaussabel D, Oommen N, Fischbach M, Shah KR, Charles J, Pascual V, Reveille JD, Tan FK.

Arthritis Rheum. 2010 Feb;62(2):589-98. doi: 10.1002/art.27224.

3.

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.

Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM.

Arthritis Rheum. 2009 Nov;60(11):3436-46. doi: 10.1002/art.24936.

4.

Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2.

Antonelli A, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Di Domenicantonio A, Ferri C.

J Rheumatol. 2012 May;39(5):979-85. doi: 10.3899/jrheum.111132. Epub 2012 Mar 15.

PMID:
22422499
5.

Type I interferon system activation and association with disease manifestations in systemic sclerosis.

Eloranta ML, Franck-Larsson K, Lövgren T, Kalamajski S, Rönnblom A, Rubin K, Alm GV, Rönnblom L.

Ann Rheum Dis. 2010 Jul;69(7):1396-402. doi: 10.1136/ard.2009.121400. Epub 2010 May 14.

PMID:
20472592
6.

Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis.

Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S.

Clin Rheumatol. 2011 Feb;30(2):231-7. doi: 10.1007/s10067-010-1610-4. Epub 2010 Nov 4.

PMID:
21049277
7.

The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.

Brkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, van den Berg W, Dalm VA, Van Daele PL, Severino A, Maria NI, Guillen S, Dik WA, Beretta L, Versnel MA, Radstake T.

Ann Rheum Dis. 2016 Aug;75(8):1567-73. doi: 10.1136/annrheumdis-2015-207392. Epub 2015 Sep 14.

PMID:
26371289
8.

Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients.

Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C.

Arthritis Res Ther. 2008;10(5):R112. doi: 10.1186/ar2510. Epub 2008 Sep 15.

9.

Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.

Steiman AJ, Gladman DD, Ibañez D, Noamani B, Landolt-Marticorena C, Urowitz MB, Wither JE.

J Rheumatol. 2015 Dec;42(12):2318-26. doi: 10.3899/jrheum.150040. Epub 2015 Nov 15.

PMID:
26568589
10.

Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis.

Assassi S, Wu M, Tan FK, Chang J, Graham TA, Furst DE, Khanna D, Charles J, Ferguson EC, Feghali-Bostwick C, Mayes MD.

Arthritis Rheum. 2013 Nov;65(11):2917-27. doi: 10.1002/art.38101.

11.

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC.

Arthritis Rheum. 2009 Oct;60(10):3098-107. doi: 10.1002/art.24803.

12.

The Th1 chemokine IP-10 in Systemic sclerosis.

Corrado A.

Clin Ter. 2014;165(6):e436-41. doi: 10.7417/CT.2014.1789.

PMID:
25524202
13.

CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment.

Bandinelli F, Del Rosso A, Gabrielli A, Giacomelli R, Bartoli F, Guiducci S, Matucci Cerinic M.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S44-9. Epub 2012 May 29.

PMID:
22691208
14.

The role of type 1 interferon in systemic sclerosis.

Wu M, Assassi S.

Front Immunol. 2013 Sep 6;4:266. doi: 10.3389/fimmu.2013.00266. Review.

15.

Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.

Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S.

J Dermatol Sci. 2004 Jun;35(1):43-51.

PMID:
15194146
16.

What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?

Assassi S, Mayes MD.

Curr Opin Rheumatol. 2013 Nov;25(6):686-91. doi: 10.1097/01.bor.0000434672.77891.41. Review.

17.

CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.

Wu M, Baron M, Pedroza C, Salazar GA, Ying J, Charles J, Agarwal SK, Hudson M, Pope J, Zhou X, Reveille JD, Fritzler MJ, Mayes MD, Assassi S.

Arthritis Rheumatol. 2017 Sep;69(9):1871-1878. doi: 10.1002/art.40171. Epub 2017 Aug 8.

PMID:
28575534
18.

Predictors of fatigue severity in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Assassi S, Leyva AL, Mayes MD, Sharif R, Nair DK, Fischbach M, Nguyen N, Reveille JD, Gonzalez EB, McNearney TA; GENISOS Study Group.

PLoS One. 2011;6(10):e26061. doi: 10.1371/journal.pone.0026061. Epub 2011 Oct 14.

19.

Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab.

López De Padilla CM, Crowson CS, Hein MS, Strausbauch MA, Aggarwal R, Levesque MC, Ascherman DP, Oddis CV, Reed AM.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5):655-63. Epub 2015 Oct 5.

PMID:
26446265
20.

An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis.

Codullo V, Baldwin HM, Singh MD, Fraser AR, Wilson C, Gilmour A, Hueber AJ, Bonino C, McInnes IB, Montecucco C, Graham GJ.

Ann Rheum Dis. 2011 Jun;70(6):1115-21. doi: 10.1136/ard.2010.137349. Epub 2011 Feb 1.

PMID:
21285114

Supplemental Content

Support Center